Quantcast
Japan approves GSK's Sotrovimab COVID-19 antibody treatment - Metro US

Japan approves GSK’s Sotrovimab COVID-19 antibody treatment

FILE PHOTO: A GSK logo is seen at the GSK research centre in Stevenage

TOKYO (Reuters) – Japan has approved GlaxoSmithKline and Vir Biotechnology’s Sotrovimab as an antibody treatment for coronavirus, Health Minister Norihisa Tamura said on Monday.

The antibody treatment is for mild to moderate COVID-19 cases which do not require oxygen supplementation, GSK said when it applied for fast-track approval this month.

(Reporting by Makiko Yamazaki, editing by Louise Heavens)

More from our Sister Sites